Cargando…

High Efficacy and Safety of Flat-Dose Ribavirin Plus Sofosbuvir/Daclatasvir in Genotype 3 Cirrhotic Patients

BACKGROUND/AIMS: Patients with genotype 3 hepatitis C virus (G3-HCV) cirrhosis are very difficult to treat compared to patients with other HCV genotypes. The optimal treatment duration and drug regimen associated with ribavirin (RBV) remain unclear. To evaluate the efficacy and safety of daclatasvir...

Descripción completa

Detalles Bibliográficos
Autores principales:	Pellicelli, Adriano, Messina, Vincenzo, Giannelli, Valerio, Distefano, Marco, Palitti, Valeria Pace, Vignally, Pascal, Tarquini, Pierluigi, Izzi, Antonio, Moretti, Alessandra, Babudieri, Sergio, Dell’Isola, Serena, Marignani, Massimo, Scifo, Gaetano, Iovinella, Vincenzo, Cariti, Giuseppe, Pompili, Maurizio, Candilo, Francesco Di, Fontanella, Luca, Ettorre, Giuseppe M., Vennarecci, Giovanni, Ippolito, Antonio Massimo, Barbarini, Giorgio
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Editorial Office of Gut and Liver 2020
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7234881/ https://www.ncbi.nlm.nih.gov/pubmed/30970444 http://dx.doi.org/10.5009/gnl18269

Ejemplares similares

Sustained virological response in patients with HCV treated with daclatasvir plus sofosbuvir, with or without ribavirin: a large, field-practice study
por: Sacco, Rodolfo, et al.
Publicado: (2020)

Sofosbuvir and daclatasvir
por: Hessel, Marleen H. M., et al.
Publicado: (2016)

HCV genotype 1a shows a better virological response to antiviral therapy than HCV genotype 1b
por: Pellicelli, Adriano M, et al.
Publicado: (2012)

Acute Interstitial Nephritis Associated with Sofosbuvir and Daclatasvir
por: Ashraf, Taha, et al.
Publicado: (2017)

Rapid reductions in prices for generic sofosbuvir and daclatasvir to treat hepatitis C
por: Hill, Andrew, et al.
Publicado: (2016)

Hepatic effect of sofosbuvir and daclatasvir in thioacetamide-induced liver injury in rats
por: Ibrahim, Mohamed A., et al.
Publicado: (2018)

Sofosbuvir/daclatasvir in the treatment of COVID-19 infection: A meta-analysis
por: Chan, Huan-Tee, et al.
Publicado: (2021)

A mini-review on sofosbuvir and daclatasvir treatment in coronavirus disease 2019
por: Shabani, M., et al.
Publicado: (2021)

Could Anti‐Hypertensive Drug Therapy Affect the Clinical Prognosis of Hypertensive Patients With COVID‐19 Infection? Data From Centers of Southern Italy
por: Sardu, Celestino, et al.
Publicado: (2020)

Hepatitis B in patients with hematological diseases: An update
por: Coluccio, Chiara, et al.
Publicado: (2017)

Women Living with HIV in Italian Prison Settings: Results from the Gender-Specific ROSE Network
por: Rastrelli, Elena, et al.
Publicado: (2023)

Treatment with Sofosbuvir and Daclatasvir (with or without Ribavirin) Improves Patient Reported Outcomes in Hepatitis C
por: de Medeiros, Lucas Pereira Jorge, et al.
Publicado: (2018)

A prospective study of daclatasvir and sofosbuvir in chronic HCV-infected kidney transplant recipients
por: Duerr, Michael, et al.
Publicado: (2019)

Treatment Outcomes for Patients Undergoing Hemodialysis with Chronic Hepatitis C on the Sofosbuvir and Daclatasvir Regimen
por: Butt, Nazish, et al.
Publicado: (2019)

Effectiveness of Sofosbuvir and Daclatasvir in treatment of Hepatitis-C: An experience of tertiary care hospital in Karachi
por: Butt, Nazish, et al.
Publicado: (2021)

The ameliorating role of sofosbuvir and daclatasvir on thioacetamide-induced kidney injury in adult albino rats
por: Moustafa, Ahmed H., et al.
Publicado: (2023)

Estimating the cost-effectiveness of daclatasvir + sofosbuvir versus sofosbuvir + ribavirin for patients with genotype 3 hepatitis C virus
por: McEwan, Phil, et al.
Publicado: (2017)

Successful recovery of associated interstitial nephritis and focal segmental glomerulosclerosis in patients with HCV and HIV treated with sofosbuvir and daclatasvir and revision of literature
por: Mirabella, Michele, et al.
Publicado: (2018)

Sofosbuvir–daclatasvir improves hepatitis C virus–induced mixed cryoglobulinemia: Upper Egypt experience
por: Hassan, Amro M, et al.
Publicado: (2018)

Efficacy and safety of sofosbuvir and daclatasvir in treatment of kidney transplantation recipients with hepatitis C virus infection
por: Xue, Yan, et al.
Publicado: (2017)

Effects of dual sofosbuvir/daclatasvir therapy on, chronic hepatitis C infected, survivors of childhood malignancy
por: El-Shabrawi, Mortada HF, et al.
Publicado: (2019)

Randomized clinical trial of nitazoxanide or sofosbuvir/daclatasvir for the prevention of SARS-CoV-2 infection
por: Sokhela, Simiso, et al.
Publicado: (2022)

Daclatasvir: potential role in hepatitis C
por: Lee, Choongho
Publicado: (2013)

Resolution of primary hepatic marginal zone lymphoma in a hepatitis C virus-infected patient treated with a direct-acting antiviral
por: Pellicelli, Adriano, et al.
Publicado: (2021)

Giant hydatid cyst of the liver with a retroperitoneal growth: a case report
por: Ettorre, Giuseppe Maria, et al.
Publicado: (2012)

Daclatasvir-based regimens in HCV cirrhosis: experience from the Italian early access program
por: Calvaruso, Vincenza, et al.
Publicado: (2019)

Daclatasvir with sofosbuvir and ribavirin for hepatitis C virus infection with advanced cirrhosis or post‐liver transplantation recurrence
por: Poordad, Fred, et al.
Publicado: (2016)

Sofosbuvir–daclatasvir improves hepatitis C virus–induced mixed cryoglobulinemia: Upper Egypt experience [Corrigendum]
Publicado: (2019)

Circulating microRNAs as predictors of response to sofosbuvir + daclatasvir + ribavirin in in HCV genotype-4 Egyptian patients
por: Hassuna, Noha Anwar, et al.
Publicado: (2022)

End Treatment Response and Sustained Viral Response in Patients With Hepatitis C Virus Receiving Sofosbuvir and Daclatasvir
por: Rahman, Attiya S, et al.
Publicado: (2023)

Efficacy of generic sofosbuvir with daclatasvir compared to sofosbuvir/ledipasvir in genotype 4 hepatitis C virus: A prospective comparison with historical control
por: Joharji, Hala, et al.
Publicado: (2022)

Daclatasvir: potential role in hepatitis C [Corrigendum]
Publicado: (2014)

Efficacy and Safety of Daclatasvir in Hepatitis C: An Overview
por: Gamal, Nesrine, et al.
Publicado: (2016)

A Review of Daclatasvir Drug–Drug Interactions
por: Garimella, Tushar, et al.
Publicado: (2016)

For a program of eradication of hepatitis C in the populations at risk (drug users and convicts)
por: Felice, A. Nava, et al.
Publicado: (2018)

Big-(wo)men, tyrants, chiefs, dictators, emperors and presidents: towards the mathematical understanding of social groups
por: dell'Isola, Francesco
Publicado: (2019)

Combination of sofosbuvir and daclatasvir in the treatment of genotype 3 chronic hepatitis C virus infection in patients on maintenance hemodialysis
por: Sperl, Jan, et al.
Publicado: (2017)

Efficacy and Safety of Generic Sofosbuvir Plus Daclatasvir and Sofosbuvir/Velpatasvir in HCV Genotype 3-Infected Patients: Real-World Outcomes From Pakistan
por: Mushtaq, Saima, et al.
Publicado: (2020)

Noncontact Body Temperature Measurement: Uncertainty Evaluation and Screening Decision Rule to Prevent the Spread of COVID-19
por: Dell’Isola, Giovanni Battista, et al.
Publicado: (2021)

Daclatasvir–sofosbuvir combination therapy with or without ribavirin for hepatitis C virus infection: from the clinical trials to real life
por: Pol, Stanislas, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_206l56r309ipr35u22k27p7q8l